EMEA clears Fabrazyme dosing changes as shortages continue
This article was originally published in Scrip
Executive Summary
The EMEA has approved revised dosing recommendations for Genzyme's Fabry disease drug Fabrazyme (agalsidase beta), in light of continued shortages of the product.